H1N1-Specific Antibody CDR Engineering for Low Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies capable of binding to influenza viruses often exhibit cross-reactivity with other viral subtypes, limiting their specificity and effectiveness in targeting H1N1 influenza viruses.
Innovation Solution
Development of a novel antibody with a specific amino acid sequence (N-FR1-CDR1-FR2-CDR2-CDR3-FR4-C) that consists of particular CDR regions (GFTFERFDMG, RFNSDDGRKSYADAVKG, and SQAYTSSTDTSSTDAEDR) ensuring high affinity and specificity to H1N1 influenza virus, minimizing cross-reactivity with other viral subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibodies are used to bind to influenza viruses, then binding capability is achieved, but cross-reactivity with other viral subtypes occurs reducing specificity
Solution Approach 1:
The patent applies local quality by specifically modifying the CDR regions (CDR1, CDR2, CDR3) of the antibody to have distinct amino acid sequences that provide targeted specificity. The CDR1 sequence is selected from specific options (e.g., GFTFERFDMG or GRTFGAPYMA), CDR2 from specific options (e.g., RFNSDDGRKSYADAVKG or GDSTYYADSMKN), and CDR3 from specific options (e.g., SQAYTSSTDTSSTDAEDR or DKWPFTGDVRSAGGYDY). These localized sequence variations in the antigen-binding regions enable the antibody to distinguish H1N1 influenza virus from other subtypes while maintaining binding capability.
2Measurement precision
If antibodies with high affinity to H1N1 are developed, then specificity to H1N1 is improved, but cross-reactivity with other subtypes increases
Solution Approach 1:
The patent applies parameter changes by systematically varying the amino acid sequences in the CDR regions to optimize the balance between H1N1 specificity and cross-reactivity reduction. Specific amino acid compositions and sequences are selected for CDR1, CDR2, and CDR3 regions based on their ability to recognize H1N1 epitopes while avoiding cross-reactive epitopes present in other influenza subtypes. This parameter optimization ensures high affinity binding to H1N1 while minimizing unwanted cross-reactions.
Data Source
AI summary
The present invention provides a novel antibody capable of binding to an influenza virus. The antibody directed to the present invention consists of the amino acid sequence represented by SEQ ID NO: 15 or SEQ ID NO: 16.